OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Collisson Discusses Developments in Gastric Cancers

March 15th 2018

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the focus of clinical trial research and genetic testing in gastrointestinal (GI) cancers.

Dr. Lopes on Immunotherapy in Head and Neck Cancer

March 15th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the role of immunotherapy for patients with head and neck cancer.

Dr. Mason on Next Steps Following 10-Year PROTECT Study Data in Prostate Cancer

March 15th 2018

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses next steps following the 10-year PROTECT study data for patients with prostate cancer.

Dr. Whitman on the Role of Pembrolizumab in Melanoma

March 15th 2018

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

March 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Dr. Hurvitz Discusses De-Escalation in HER2+ Breast Cancer

March 15th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses de-escalation in HER2-positive breast cancer.

Dr. Barrientos on the Impact of Combinations in CLL

March 15th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia.

Dr. Atreya on How the NCCN Guidelines Have Impacted Treatment Options in mCRC

March 14th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Dr. Kim Addresses Concerns About Hyperprogression in NSCLC

March 14th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the prevalence of hyperprogression and pseudoprogression in patients who receive immunotherapy.

Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

March 14th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Dr. West on Relationship Between Diet and Endometrial Cancer

March 13th 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the relationship between diet and endometrial cancer.

Dr. Slovin on the Promise of GnRH Antagonists in Prostate Cancer

March 13th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the promise of GnRH antagonists in prostate cancer.

Dr. Lonial on Differentiating Patients With Smoldering and Multiple Myeloma

March 13th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses differentiating patients with smoldering myeloma and multiple myeloma.

Dr. Bosse Discusses Bone-Targeted Agents in RCC

March 13th 2018

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Dr. Crane on the Toxicity Profile of Combinations for Ovarian Cancer

March 13th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the toxicity profile of combination regimens for patients with ovarian cancer.

Dr. Clarke on the State of Biomarkers in NSCLC

March 13th 2018

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the evolution of biomarkers in directing treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Pecot on Immunotherapy Combinations in NSCLC

March 13th 2018

Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses promising combinations for patients with non–small cell lung cancer (NSCLC).

Dr. Verma on Incorporating Biosimilars Into Practice

March 13th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses incorporating biosimilars in oncology practice.

Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant

March 13th 2018

Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.

Dr. Goy Discusses BTK Inhibitors in MCL

March 13th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of patients with mantle cell lymphoma (MCL).